Medtronic DES trial
This article was originally published in The Gray Sheet
Executive Summary
Firm announces Oct. 19 an 8,000-patient, 200-site clinical trial assessing and comparing safety measures of its Endeavor zotarolimus-eluting stent and Johnson & Johnson's Cypher sirolimus-eluting stent. The primary endpoint for the PROTECT study will be overall stent thrombosis, and it will evaluate use of the stents in a "real world" population. Drug-eluting stents have come under fire in recent months due to concerns that thrombosis rates in clinical practice exceed levels seen in the products' pivotal trials (1see related story, p. 3). Endeavor, available in Europe and other international markets since 2005, is on track for FDA approval in 2007...
You may also be interested in...
Editorial Reflects Conservative Approach To Use Of Drug-Eluting Stents
As apprehension over the use of drug-eluting stents grows, two cardiologists last week fired another salvo, asserting that the overuse of DES is placing too many patients in harm's way for little or no added benefit
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.